Insider Selling: Stoke Therapeutics (NASDAQ:STOK) Insider Sells $114,767.08 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 3,662 shares of the firm’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $31.34, for a total value of $114,767.08. Following the sale, the insider directly owned 19,798 shares in the company, valued at approximately $620,469.32. This represents a 15.61% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Barry Ticho also recently made the following trade(s):

• On Thursday, December 4th, Barry Ticho sold 1,696 shares of Stoke Therapeutics stock. The stock was sold at an average price of $30.87, for a total value of $52,355.52.
• On Wednesday, December 3rd, Barry Ticho sold 2,014 shares of Stoke Therapeutics stock. The stock was sold at an average price of $30.65, for a total transaction of $61,729.10.
• On Tuesday, December 2nd, Barry Ticho sold 2,006 shares of Stoke Therapeutics stock. The shares were sold at an average price of $29.78, for a total transaction of $59,738.68.
• On Monday, November 3rd, Barry Ticho sold 5,931 shares of Stoke Therapeutics stock. The stock was sold at an average price of $25.72, for a total transaction of $152,545.32.

Stoke Therapeutics Trading Down 0.6%

STOK opened at $30.87 on Monday. The stock has a market capitalization of $1.76 billion, a P/E ratio of 46.07 and a beta of 1.14. Stoke Therapeutics, Inc. has a 12 month low of $5.35 and a 12 month high of $38.69. The firm’s fifty day simple moving average is $29.03 and its 200 day simple moving average is $19.97.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.11). The firm had revenue of $10.63 million during the quarter, compared to analyst estimates of $6.06 million. Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. On average, equities research analysts predict that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on STOK. JPMorgan Chase & Co. boosted their target price on Stoke Therapeutics from $15.00 to $25.00 and gave the company a “neutral” rating in a research note on Monday, November 3rd. Wedbush lifted their price objective on shares of Stoke Therapeutics from $22.00 to $32.00 and gave the company an “outperform” rating in a report on Wednesday, November 5th. Chardan Capital raised shares of Stoke Therapeutics to a “strong-buy” rating in a research report on Wednesday, November 19th. Needham & Company LLC raised their target price on shares of Stoke Therapeutics from $22.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, October 10th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Stoke Therapeutics in a research note on Monday, December 1st. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, Stoke Therapeutics currently has an average rating of “Buy” and a consensus target price of $31.00.

Institutional Investors Weigh In On Stoke Therapeutics

Several large investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its stake in shares of Stoke Therapeutics by 7.4% in the third quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company’s stock valued at $74,351,000 after buying an additional 217,616 shares in the last quarter. Marshall Wace LLP lifted its stake in Stoke Therapeutics by 7.9% in the second quarter. Marshall Wace LLP now owns 2,300,554 shares of the company’s stock valued at $26,111,000 after acquiring an additional 168,771 shares during the last quarter. Siren L.L.C. grew its position in shares of Stoke Therapeutics by 12.4% in the 1st quarter. Siren L.L.C. now owns 2,247,347 shares of the company’s stock valued at $14,945,000 after acquiring an additional 247,347 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of Stoke Therapeutics by 21.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock worth $11,053,000 after purchasing an additional 293,072 shares during the last quarter. Finally, Polar Capital Holdings Plc increased its stake in shares of Stoke Therapeutics by 49.8% during the 3rd quarter. Polar Capital Holdings Plc now owns 1,323,470 shares of the company’s stock worth $31,102,000 after purchasing an additional 439,824 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.